Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics) - Volume 21, Issue 2, 2024

Genomic information plays an essential role in personalized medicine, with the main objective of determining risk and predisposition to disease, as well as guiding diagnosis, selection, and prioritization of therapeutic options, and even predicting prognosis. Research in the second half of the 20th century allowed genomics to move from the laboratory to clinical practice. The Human Genome Project showed the structure of the gen Read More

Polycystic Ovary Syndrome (PCOS) is a condition affecting women of reproductive age, characterized by a heterogeneous array of symptoms. This study aims to examine the role of Precision and Personalized Medicine (PPM) in managing PCOS, given the diverse manifestations of the disease and any genetic factors involved. In this review, we have analyzed the existing literature on the heterogeneity in PCOS symptoms, effort Read More

Type 2 Diabetes Mellitus (T2DM) has been a severe public health issue worldwide for many years. The primary cause and risk factor of T2DM is hereditary and complicated interaction between epigenetics. Identification and understanding of genetic markers may help to detect, prevent, and manage T2DM. This review examined the effect of single-gene and gene-gene interactions for predicting diabetes mellitus. Based on th Read More

Introduction Variability in the effectiveness of metformin treatment among individuals with type 2 diabetes mellitus (T2DM) has been linked to various genetic factors. Understanding the genetic mechanisms underlying the action of metformin can greatly aid the personalized management of T2DM. Our investigation aimed to explore the impact of genetic variations in the organic cation transporters (OCT1 and OCT3) genes Read More

Introduction Metformin is a key treatment for type 2 diabetes, often linked to oxidative stress and genetic factors like GSTM1 and GSTT1 variations. Methods We studied 150 subjects, examining how their deletion polymorphisms in these genes correlate with Met treatment response. Those with GSTM1/T1 deletions (-/-) had a higher T2DM risk (2.71-fold, P=0.005). Results Met responders with GSTM1(16bp) deletions had lower glu Read More

Background Osteoporosis is a multifactorial disorder where genetic and environmental factors contribute to changes in bone mineral density. Several genetic polymorphisms are associated with low bone mineral density and osteoporosis risk, including estrogen receptor-α rs2234693 and rs9340799 single nucleotide polymorphisms. Objective To determine the allele frequencies of these polymorphisms among postmenopa Read More